放射性配体治疗市场 - 2017-2027年全球行业规模、份额、趋势、机会和预测，按适应症、产品、生物标志物、终端用户、公司和地区划分

在2023-2027年的预测期内，全球放射性配体治疗市场预计将出现令人瞩目的增长。主要因素，包括各种类型癌症发病率的上升和对阿尔法放射免疫疗法认识的提高，正在推动该市场的增长。放射性免疫疗法是一种治疗某些类型癌症的先进方法。它向目标癌细胞提供辐射，而对健康细胞的影响可以忽略不计。这种疗法为那些没有充分治疗选择的癌症患者提供了改善生命的治疗。支持市场增长的其他因素有：世界人口增长、庞大的患者群体、技术进步带来的产品创新和开发的上升、政府投资的增加、医疗领域放射性同位素的增加、人均医疗支出的上升、合併和战略收购数量的增加，以及大量的临床试验。

各种类型癌症的发病率上升

癌症是全世界的主要死因。各种类型的癌症，特别是前列腺癌和神经内分泌肿瘤的发病率不断上升，正在推动市场的增长。根据国际癌症研究机构（IARC）的数据，2018年，全球约有1700万新的癌症病例和950万癌症相关的死亡病例。前列腺癌和神经内分泌肿瘤是最常见的癌症，特别是在美国男性。根据美国癌症协会的数据，2019年，在美国发现了大约174,650个前列腺癌新病例。由于患癌症的病人数量增加，对放射性配体疗法的需求激增，推动了市场的增长。

对阿尔法放射免疫疗法认识的提高和研发活动的增加

阿尔法放射免疫疗法是一种有针对性的抗肿瘤疗法，能够提供成功的治疗。因此，人们和医生对阿尔法放射免疫疗法的认识的提高正在推动市场的增长。此外，用于治疗各种癌症类型的放射性配体疗法的研究和开发的增加，正在促进全球放射性配体疗法市场的发展。由于不断的研究和开发活动，出现了一些新的方法，如Lutetium 177、前列腺特异性膜抗原（PSMA）等，用于治疗癌症。例如，POINT Biopharma Global Inc.正计划以PNT2003药物进入放射性配体治疗市场，该药物目前正处于临床试验的最后阶段。

政府不断增加的投资和上升的倡议

政府为减少癌症负担而增加的投资和各种倡议正在推动市场的增长。例如，在2021年，欧盟委员会推出了欧洲战胜癌症计划，旨在提供癌症服务，重点是疾病预防和早期诊断。后来，在2022年，欧洲政府打算为癌症研究和护理投入超过42亿美元。

可用的定制服务

利用给定的市场数据，TechSci Research根据公司的具体需求提供定制服务。该报告可提供以下定制选项：

公司信息

• 其他市场参与者（最多5家）的详细分析和概况。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19对全球放射性配体治疗市场的影响

第五章：客户的声音

第六章：临床试验分析

第七章 ：全球放射性配体治疗市场前景

• 市场规模和预测
  • 按价值
• 市场份额与预测
  • 按适应症（前列腺癌、神经内分泌肿瘤、其他）分类
  • 按产品（Lutathera, Zytiga, Xtandi, Xofigo）分类
  • 按生物标志物（前列腺特异性膜抗原、Ki 67表达和分级、细胞色素P450 17A1抑制剂）分类
  • 按终端用户（生物技术和制药公司、学术和研究机构、其他）分类
  • 按地区
  • 按公司分类 (2021年)
• 市场地图

第8章：北美放射配体治疗市场前景

• 市场规模和预测
  • 按价值分类
• 市场份额与预测
  • 按适应症分类
  • 按产品分类
  • 按生物标志物分类
  • 按终端用户
  • 按国家分类
• 北美洲：国家分析
  • 美国
  • 美国
  • 墨西哥

第九章：欧洲放射性配体治疗市场前景

• 市场规模和预测
  • 按价值计算
• 市场份额与预测
  • 按适应症分类
  • 按产品分类
  • 按生物标志物分类
  • 按终端用户
  • 按国家分类
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第十章：亚太地区放射性配体治疗市场前景

• 市场规模和预测
  • 按价值计算
• 市场份额与预测
  • 按适应症分类
  • 按产品分类
  • 按生物标志物分类
  • 按终端用户
  • 按国家分类
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第十一章 ：南美放射配体治疗市场前景

• 市场规模和预测
  • 按价值计算
• 市场份额与预测
  • 按适应症分类
  • 按产品分类
  • 按生物标志物分类
  • 按终端用户
  • 按国家分类
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十二章 ：中东和非洲放射配体治疗市场展望

• 市场规模和预测
  • 按价值计算
• 市场份额和预测
  • 按适应症分类
  • 按产品分类
  • 按生物标志物分类
  • 按终端用户
  • 按国家分类
• MEA: 国家分析
  • 南非 放射性配体治疗
  • 沙特阿拉伯 放射性配体治疗
  • 阿联酋 放射性配体治疗

第十三章 ：市场动态

• 驱动力
• 挑战

第十四章：市场趋势与发展

第十五章 ：竞争格局(包括SWOT分析)

• 诺华国际公司（Novartis International, AG
• 强生公司
• 辉瑞公司（Pfizer）。
• Amneal Pharmaceuticals LLC.
• POINT Biopharma Global Inc
• Fusion Pharmaceuticals Inc.
• Clovis Oncology, Inc.
• Telix Pharmaceuticals Limited
• Lantheus Holdings, Inc.
• Progenics Pharmaceuticals
• 拜耳公司

第16章 ：战略建议

The global radioligand therapy market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of various types of cancers and increasing awareness of alpha radioimmunotherapy, are propelling the growth of the market. Radioligand therapy is an advanced approach to treat certain kinds of cancer. It provides radiation to targeted cancer cells, with a negligible effect on healthy cells. This therapy provides life-enhancing treatment for patients with cancer who have inadequate therapeutic options. The other factors supporting the market's growth are a growing world population, large patient pool, rising product innovation and development due to technological advancements, increasing government investments, increasing radioisotopes in healthcare, rising per capita healthcare expenditure, growing number of mergers and strategic acquisitions, and a large number of clinical trials.

Rising Incidence of Various types of Cancers

Cancer is a leading cause of death across the world. The growing prevalence of various types of cancers, especially prostate cancer and neuroendocrine tumors, is bolstering the growth of the market. According to the International Agency for Research on Cancer (IARC), in 2018, there were approximately 17.0 million new cancer cases and 9.5 million cancer-related deaths across the world. Prostate cancer and neuroendocrine tumors are the most common cancer, especially in American men. As per the American Cancer Society, in 2019, around 174,650 new cases of prostate cancer were detected in the U.S. Owing to the rise in the number of patients suffering from cancer, the surge in demand for radioligand therapy is driving the growth of the market.

Increased Awareness of Alpha Radioimmunotherapy and Rise in R&D Activities

Alpha Radioimmunotherapy is a targeted anti-tumor therapy that provides successful treatments. Therefore, the rise in awareness among people and physicians regarding alpha-radioimmunotherapy is bolstering the growth of the market. In addition, the rise in research & development of radioligand therapy to treat a wide range of cancer types is augmenting the global radioligand therapy market, globally. The advent of novel methods, such as lutetium 177, prostate-specific membrane antigen (PSMA), and others, for the treatment of cancer is due to continuous research and development activities. For instance, POINT Biopharma Global Inc. is planning to enter the market for radioligand therapy with the PNT2003 drug, which is presently in the last phases of clinical trials.

Increasing Investments and rising Initiatives by the Government

The rise in investments and various initiatives by governments to reduce the cancer burden is propelling the growth of the market. For instance, in 2021, the European Commission launched Europe's Beating Cancer Plan, which aims to offer cancer services with a focus on disease prevention and early diagnosis. Later, in 2022, the European government intended to pour over $4.2 billion into cancer research and care.

Market Segmentation

The global radioligand therapy market is segmented into indication, product, biomarker, end user, and company. Based on indication, the market is divided into prostate cancer, neuroendocrine tumor, and others. Based on product, the market is divided into lutathera, zytiga, xtandi, and xofigo. Based on a biomarker, the market is divided into prostate-specific membrane antigen, Ki 67 expression and grading, and cytochrome P450 17A1 inhibitor. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising cases of prostate cancer in the country.

Market Players

Novartis International, AG, Johnson & Johnson, Pfizer, Inc., Amneal Pharmaceuticals LLC., POINT Biopharma Global Inc, Fusion Pharmaceuticals Inc., Clovis Oncology, Inc., Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., Progenics Pharmaceuticals, and Bayer AG are some of the leading companies operating in the market.

Report Scope

In this report, global radioligand therapy market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Radioligand Therapy Market, By Indication:

• Prostate Cancer
• Neuroendocrine Tumor
• Others

Radioligand Therapy Market, By Product:

• Lutathera
• Zytiga
• Xtandi
• Xofigo

Radioligand Therapy Market, By Biomarker:

• Prostate-Specific Membrane Antigen
• Ki 67 Expression and Grading
• Cytochrome P450 17A1 Inhibitor

Radioligand Therapy Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Radioligand Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Europe & CIS
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Radioligand Therapy Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Radioligand Therapy Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Radioligand Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Prostate Cancer, Neuroendocrine Tumor, Others)
  • 7.2.2. By Product (Lutathera, Zytiga, Xtandi, Xofigo)
  • 7.2.3. By Biomarker (Prostate-Specific Membrane Antigen, Ki 67 Expression and Grading, Cytochrome P450 17A1 Inhibitor)
  • 7.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 7.2.5. By Region
  • 7.2.6. By Company (2021)
• 7.3. Market Map

8. North America Radioligand Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Product
  • 8.2.3. By Biomarker
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Radioligand Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Biomarker
      • 8.3.1.2.4. By End User
  • 8.3.2. Canada Radioligand Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Biomarker
      • 8.3.2.2.4. By End User
  • 8.3.3. Mexico Radioligand Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Biomarker
      • 8.3.3.2.4. By End User

9. Europe Radioligand Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Product
  • 9.2.3. By Biomarker
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. France Radioligand Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Biomarker
      • 9.3.1.2.4. By End User
  • 9.3.2. Germany Radioligand Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Biomarker
      • 9.3.2.2.4. By End User
  • 9.3.3. United Kingdom Radioligand Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Biomarker
      • 9.3.3.2.4. By End User
  • 9.3.4. Italy Radioligand Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Indication
      • 9.3.4.2.2. By Product
      • 9.3.4.2.3. By Biomarker
      • 9.3.4.2.4. By End User
  • 9.3.5. Spain Radioligand Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Indication
      • 9.3.5.2.2. By Product
      • 9.3.5.2.3. By Biomarker
      • 9.3.5.2.4. By End User

10. Asia-Pacific Radioligand Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Product
  • 10.2.3. By Biomarker
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Radioligand Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Biomarker
      • 10.3.1.2.4. By End User
  • 10.3.2. India Radioligand Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Biomarker
      • 10.3.2.2.4. By End User
  • 10.3.3. Japan Radioligand Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Biomarker
      • 10.3.3.2.4. By End User
  • 10.3.4. South Korea Radioligand Therapy Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Indication
      • 10.3.4.2.2. By Product
      • 10.3.4.2.3. By Biomarker
      • 10.3.4.2.4. By End User
  • 10.3.5. Australia Radioligand Therapy Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Indication
      • 10.3.5.2.2. By Product
      • 10.3.5.2.3. By Biomarker
      • 10.3.5.2.4. By End User

11. South America Radioligand Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Indication
  • 11.2.2. By Product
  • 11.2.3. By Biomarker
  • 11.2.4. By End User
  • 11.2.5. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Radioligand Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Indication
      • 11.3.1.2.2. By Product
      • 11.3.1.2.3. By Biomarker
      • 11.3.1.2.4. By End User
  • 11.3.2. Argentina Radioligand Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Indication
      • 11.3.2.2.2. By Product
      • 11.3.2.2.3. By Biomarker
      • 11.3.2.2.4. By End User
  • 11.3.3. Colombia Radioligand Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Indication
      • 11.3.3.2.2. By Product
      • 11.3.3.2.3. By Biomarker
      • 11.3.3.2.4. By End User

12. Middle East and Africa Radioligand Therapy Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Indication
  • 12.2.2. By Product
  • 12.2.3. By Biomarker
  • 12.2.4. By End User
  • 12.2.5. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Radioligand Therapy Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Indication
      • 12.3.1.2.2. By Product
      • 12.3.1.2.3. By Biomarker
      • 12.3.1.2.4. By End User
  • 12.3.2. Saudi Arabia Radioligand Therapy Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Indication
      • 12.3.2.2.2. By Product
      • 12.3.2.2.3. By Biomarker
      • 12.3.2.2.4. By End User
  • 12.3.3. UAE Radioligand Therapy Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Indication
      • 12.3.3.2.2. By Product
      • 12.3.3.2.3. By Biomarker
      • 12.3.3.2.4. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

• 15.1. Novartis International, AG
• 15.2. Johnson & Johnson
• 15.3. Pfizer, Inc.
• 15.4. Amneal Pharmaceuticals LLC.
• 15.5. POINT Biopharma Global Inc
• 15.6. Fusion Pharmaceuticals Inc.
• 15.7. Clovis Oncology, Inc.
• 15.8. Telix Pharmaceuticals Limited
• 15.9. Lantheus Holdings, Inc.
• 15.10. Progenics Pharmaceuticals
• 15.11. Bayer AG

16. Strategic Recommendations